Geneoscopy, a company focused on next-generation gastrointestinal diagnostic tests, successfully closed a $105 million Series C funding round. Bio-Rad Laboratories led this significant investment, demonstrating its strategic interest in advancing innovative diagnostic solutions.
This funding is intended to power the development and commercialization of Geneoscopy's diagnostic tests, including an FDA-approved, non-invasive colorectal cancer screening test. The test utilizes Bio-Rad's digital PCR platform, highlighting a key synergy between the companies.
The investment underscores Bio-Rad's commitment to expanding its presence in clinical diagnostics through strategic partnerships. By supporting Geneoscopy, Bio-Rad is aligning with innovation in a critical area of patient care and strengthening the application of its core digital PCR technology.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.